CoChat
Sign Up
Cited by 16Bacteriophages and microbial interactionsVirus-based gene therapy researchCRISPR and Genetic Engineering

Bacteriophage Bioengineering: A Transformative Approach for Targeted Drug Discovery and Beyond

Open access
Cui, Longzhu, Veeranarayanan, Srivani, Thitiananpakorn, Kanate, Wannigama, Dhammika Leshan·2023·Pathogens
DOI 10.3390/pathogens12091179PMC PMC10534869
Open this paper in CoChat — free accountOpen PDF

Abstract

Bacteriophages, the viruses that infect and replicate within bacteria, have long been recognized as potential therapeutic agents against bacterial infections [...]

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pathogens12091179

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Advances in synthetic biology allow phages to be engineered as programmable anticancer agents capable of remodeling the microbiome or delivering immunomodulatory payloads.

    “Advances in synthetic biology now allow phages to be engineered as programmable anticancer agents, capable of remodeling the microbiome or delivering immunomodulatory payloads [30–33]”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [31]

    The paper’s main text (page unavailable) describes genetically engineered phages and proposes modifying them to selectively target and destroy cancer cells. It also discusses sparing beneficial microbiota and adding payloads, but does not describe anticancer phages that remodel the microbiome or deliver immunomodulatory payloads. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Phages can deliver targeted therapeutic payloads.

    “Phages can eliminate cancer-associated bacteria, remodel the tumor microenvironment, enhance antitumor immunity, and deliver targeted therapeutic payloads.”

    From Phage therapy in oncology: opportunities for cancer prevention and treatment (2026) · cites this paper as [31]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 21

  1. [1]Kiga K. Tan X.-E. Ibarra-Chávez R. Watanabe S. Aiba Y. Sato’o Y. Li F.-Y. Sasahara T. Cui B. Kawauchi M. Development of CRISPR-Cas13a-based antimicrobials capable of sequence-specific killing of target bacteria Nat. Commun. 2020 11 2934 10.1038/s41467-020-16731-6 32523110 PMC7287087 · DOI
  2. [2]Yosef I. Manor M. Kiro R. Qimron U. Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria Proc. Natl Acad. Sci. USA 2015 112 7267 7272 10.1073/pnas.1500107112 26060300 PMC4466736 · DOI
  3. [3]Meile S. Du J. Dunne M. Kilcher S. Loessner M.J. Engineering therapeutic phages for enhanced antibacterial efficacy Curr. Opin. Virol. 2021 52 182 191 10.1016/j.coviro.2021.12.003 34952266 · DOI
  4. [4]Gordillo Altamirano F.L. Barr J.J. Phage Therapy in the Postantibiotic Era Clin. Microbiol. Rev. 2019 32 e00066-18 10.1128/CMR.00066-18 30651225 PMC6431132 · DOI
  5. [5]Kilcher S. Loessner M.J. Engineering Bacteriophages as Versatile Biologics Trends Microbiol. 2019 27 355 367 10.1016/j.tim.2018.09.006 30322741 · DOI
  6. [6]Zhang X. Zhang C. Liang C. Li B. Meng F. Ai Y. CRISPR-Cas9 Based Bacteriophage Genome Editing Microbiol. Spectr. 2022 10 e0082022 10.1128/spectrum.00820-22 35880867 PMC9430736 · DOI
  7. [7]Du J. Meile S. Baggenstos J. Jäggi T. Piffaretti P. Hunold L. Matter C.I. Leitner L. Kessler T.M. Loessner M.J. Enhancing bacteriophage therapeutics through in situ production and release of heterologous antimicrobial effectors Nat. Commun. 2023 14 4337 10.1038/s41467-023-39612-0 37474516 PMC10359290 · DOI
  8. [8]Jia H.J. Jia P.P. Yin S. Bu L.K. Yang G. Pei D.S. Engineering bacteriophages for enhanced host range and efficacy: Insights from bacteriophage-bacteria interactions Front. Microbiol. 2023 14 1172635 10.3389/fmicb.2023.1172635 37323893 PMC10264812 · DOI
  9. [9]Łobocka M. Dąbrowska K. Górski A. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future BioDrugs 2021 35 255 280 10.1007/s40259-021-00480-z 33881767 PMC8084836 · DOI
  10. [10]Abdelrahman F. Easwaran M. Daramola O.I. Ragab S. Lynch S. Oduselu T.J. Khan F.M. Ayobami A. Adnan F. Torrents E. Phage-Encoded Endolysins Antibiotics 2021 10 124 10.3390/antibiotics10020124 33525684 PMC7912344 · DOI
  11. [11]Gondil V.S. Harjai K. Chhibber S. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections Int. J. Antimicrob. Agents 2019 55 105844 10.1016/j.ijantimicag.2019.11.001 31715257 · DOI
  12. [12]Al-Hindi R.R. Teklemariam A.D. Alharbi M.G. Alotibi I. Azhari S.A. Qadri I. Alamri T. Harakeh S. Applegate B.M. Bhunia A.K. Bacteriophage-Based Biosensors: A Platform for Detection of Foodborne Bacterial Pathogens from Food and Environment Biosensors 2022 12 905 10.3390/bios12100905 36291042 PMC9599427 · DOI
  13. [13]Paramasivam K. Shen Y. Yuan J. Waheed I. Mao C. Zhou X. Advances in the Development of Phage-Based Probes for Detection of Bio-Species Biosensors 2022 12 30 10.3390/bios12010030 35049658 PMC8773867 · DOI
  14. [14]Ibarra-Chávez R. Reboud J. Penadés J.R. Cooper J.M. Phage-Inducible Chromosomal Islands as a Diagnostic Platform to Capture and Detect Bacterial Pathogens Adv. Sci. 2023 10 e2301643 10.1002/advs.202301643 37358000 PMC10460865 · DOI
  15. [15]He X. Yang Y. Guo Y. Lu S. Du Y. Li J.-J. Zhang X. Leung N.L.C. Zhao Z. Niu G. Phage-Guided Targeting, Discriminative Imaging, and Synergistic Killing of Bacteria by AIE Bioconjugates J. Am. Chem. Soc. 2020 142 3959 3969 10.1021/jacs.9b12936 31999445 · DOI
  16. [16]Ragothaman M. Yoo S.Y. Engineered Phage-Based Cancer Vaccines: Current Advances and Future Directions Vaccines 2023 11 919 10.3390/vaccines11050919 37243023 PMC10222954 · DOI
  17. [17]Shen Y. Wang J. Li Y. Yang C.-T. Zhou X. Modified Bacteriophage for Tumor Detection and Targeted Therapy Nanomaterials 2023 13 665 10.3390/nano13040665 36839030 PMC9963578 · DOI
  18. [18]Labrie S.J. Samson J.E. Moineau S. Bacteriophage resistance mechanisms Nat. Rev. Microbiol. 2010 8 317 327 10.1038/nrmicro2315 20348932 · DOI
  19. [19]Oromí-Bosch A. Antani J.D. Turner P.E. Developing Phage Therapy That Overcomes the Evolution of Bacterial Resistance Annu. Rev. Virol. 2023 10 10.1146/annurev-virology-012423-110530 37268007 · DOI
  20. [20]Hitchcock N.M. Nunes D.D.G. Shiach J. Hodel K.V.S. Barbosa J.D.V. Rodrigues L.A.P. Coler B.S. Soares M.B.P. Badaró R. Current Clinical Landscape and Global Potential of Bacteriophage Therapy Viruses 2023 15 1020 10.3390/v15041020 37113000 PMC10146840 · DOI
  21. [21]Petrovic Fabijan A. Iredell J. Danis-Wlodarczyk K. Kebriaei R. Abedon S.T. Translating phage therapy into the clinic: Recent accomplishments but continuing challenges PLoS Biol. 2023 21 e3002119 10.1371/journal.pbio.3002119 37220114 PMC10204993 · DOI

Cited by

Sorted by citations

Authors
Cui, L., Veeranarayanan, S., Thitiananpakorn, K., & Wannigama, D. L.
Affiliations
  • Jichi Medical University (JP)
  • Yamagata Prefectural Central Hospital (JP)
Corresponding author
Cui, Longzhu
ORCID
Venue
Pathogens
Publisher
MDPI AG
Published
2023-09-20
Volume
12
Issue
9
Pages
1179
ISSN
2076-0817 (ISSN-L)
DOI
10.3390/pathogens12091179
PMC
PMC10534869
OpenAlex
W4386894323
Cited by
16
References
0
Citations by year
2026: 3 · 2025: 4 · 2024: 8 · 2023: 1
FWCI
2.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Pathogens (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • AMED (JP21gm1610002, JP22ae0121045, JPJ009237)
  • Cabinet Office, Government of Japan (JP21gm1610002, JP22ae0121045, JPJ009237)
Topics
  • Physical Sciences › Environmental Science › Ecology › Bacteriophages and microbial interactions
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Keywords
bacteriophages, phage therapy, targeted drug discovery, antibacterial agents, bacterial infection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review